ATG16L1 Prevents Lethal T-Cell Alloreactivity Mediated By Dendritic Cells  by Shono, Yusuke et al.
Figure 3. Reduced nutritional intake appears to drive loss of Blautia in allo BMT recipients, A) Ninety-four allo BMT patients were evaluated weekly for changes in the
intestinal microbiota during transplant hospitalization. Blautia abundance is depicted by a solid black line with 95% conﬁdence bands shown in gray constructed
using moving average ﬁltering. B) Daily nutritional and microbiota analysis was collected in 5 allo BMT patients during transplant hospitalization, and abundance of
Blautia analyzed for stool samples stratiﬁed by kCal consumption. C) Stool abundance of Clostridials (the order to which Blautia belongs) was assayed in mice before
and after one week of 25% reduction m food consumption.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S22eS26 S23Our results have identiﬁed the microbiota as a potent ther-
apeutic target that can be recruited to signiﬁcantly reduce
GVHD. Approaches to potentially translate these ﬁndings
include investigating the safety of introduction of Blautia to
allo BMT recipients, or alternatively developing nutritional
strategies to support endogenous Blautia during the trans-
plantation process.
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Invariant natural killer T (iNKT) cells are a rare but potent
immunomodulatory subset of lymphocytes in humans (TCRa
Va24-Ja18) and mice (TCRa Va14-Ja18). It has been shown
previously that host iNKT cells require interaction with
CD4+FoxP3+ regulatory T cells to protect from acute GVHD
after conditioning with total lymphoid irradiation and anti-
thymocyte globulin (Pillai et al., Blood 2009). In this study, we
investigated the role of highly puriﬁed adoptively transferred
donor-derived CD4+ iNKT cells in the setting of myeloablative
conditioning. Balb/c (H-2Kd) recipient mice were irradiated
with 8 Gy and transplanted with T cell-depleted bonemarrow
together with 1x106 CD4/CD8 T lymphocytes (Tcon) from
C57Bl/6 (H-2Kb) donor mice. Mice co-injected with as low as
5x104 highly puriﬁed (>99%) CD4+ iNKT cells showed a sig-
niﬁcant survival beneﬁt compared to mice receiving Tcon
alone (p¼.002). Consistently, weight and GVHD score
improved in mice that received CD4+ iNKT cells. Signal in-
tensity derived from expanding luciferase expressing allor-
eactive Tcon was signiﬁcantly lower in animals treated with
CD4+ iNKT cells demonstrating inhibition of proliferation of
alloreactive Tcon through CD4+ iNKT cells (p<.0001). In vivo
CFSE proliferation assay conﬁrmed decreased Tcon prolifera-
tion in peripheral lymph nodes (p<.0001), mesenteric lymph
nodes (p¼.03) and spleen (p¼.0005). In addition, Tcon from
CD4+ iNKT cell treated mice showed a signiﬁcantly lowerexpression of activation markers CD44 and CD25. Interest-
ingly, animals treated with CD4+ iNKT cells showed a robust
expansion of donor-derived Neurophilin-1-/lowCD4+FoxP3+ T
cells in peripheral lymph nodes, mesenteric lymph nodes,
spleen, gut, liver and skin. Moreover, CD4+ iNKT cells derived
from NKG2D-/- animals were signiﬁcantly less effective in
preventing acute GVHD lethality (WT vs. NKG2D-/- p¼.003).
Co-injection of CD4+ iNKT cells did not abrogate GVL reactions
of Tcon towards BCL1 cells measured by bioluminescence
imaging (p¼ns). With a-GalCer and IL-2 in vitro expanded
CD4+ iNKT cells had the same protective effect from lethal
acute GVHD compared to freshly isolated CD4+ iNKT cells
(p¼ns). We conclude that low numbers of highly puriﬁed
CD4+ iNKT cells protect from lethal acute GVHD in mice
through a dramatic expansion of donor-derived CD4+FoxP3+
regulatory T cells with retained GVL effect. Despite the fact
that iNKT cells are a rare cell population, the feasibility of in
vitro expansion with retained functionality of CD4+ iNKT cells
provide the basis for clinical translation.
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The role of autophagy in GVHD is unknown.We used a MHC-
disparate allo-HSCT model (B10.BR into B6) and compared
wild-type (WT) vs ATG16L1HM (hypomorphic (HM) for
expression of the ATG16L1 protein) recipients. HM recipients
developed signiﬁcantly increased GVHD mortality (Figure A,
P < 0.001) and morbidity. This was associated with signiﬁ-
cantly increased levels of inﬂammatory cytokines, including
TNF-alpha and IL-12 (P < 0.05). CFSE analysis demonstrated
signiﬁcantly increased proliferation and activation of allor-
eactive donor T cells in HM recipients. Alloreactive donor T
cells in HM recipients expressed higher levels of LPAM-1,
Figure. ATG16C1HM recipients have increased mortality after allo-HSCT with increased expression of activation/maturation molecules in recipient DCs. (A, B)
Lethally irradiated C57BL/6 wild-type or ATG16L1HM recipients were transplanted with B10.BR TCD BM cells with 2  106 B10.BR T cells. (A) Survival. (B) Histogram
overlays of activation/maturation molecules expression of recipient DCs. Recipient spleens were harvested on day 7 after allo-HSCT. Data are representative of two
independent experiments.***, P < 0.001.
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correlated with signiﬁcantly increased numbers of inﬁl-
trating donor T cells in the intra-epithelial compartment of
the small intestines (P< 0.05). HM recipients had greater loss
of intestinal integrity as demonstrated by increased intesti-
nal permeability after oral FITC-dextran gavage (P < 0.01)
and increased bacterial colony growth from spleen and blood
(P < 0.05). To further assess the increased alloreactivity of
donor Tcells in HM recipients, we analyzed recipient-derived
dendritic cells (DC) in HM vs WT recipients and noted a)
increased numbers, b) increased expression of activation/
maturation molecules (CD40, CD80 and CD86; Figure B) by
ﬂow cytometry and transcriptome microarray and c)
increased alloactivation of donor T cells when tested in a
mixed lymphocyte reaction. In addition, we demonstrated
that in vitro culture of DCs with an autophagy-inducing drug
(resveratrol) resulted in decreased expression of activation/
maturation molecules (P < 0.001).
To determine if ATG16L1 deﬁciency in recipient DCs is suf-
ﬁcient, we performed experiments with CD11c-Cre/Atg16l1f/f
recipients (in which the ATG16L1 deﬁciency is restricted to
CD11c+ DC in the recipient) and found increased GVHD.
Finally, to assess whether ATG16L1 contributes to GVHD
through its role in autophagy, we treated allo-HSCT re-
cipients with an autophagy inhibitor (Lys05; 10 mg/kg i.p.,
days -3 to 30) and found signiﬁcantly increased GVHD.
In conclusion, these preclinical studies demonstrate that loss
of ATG16L1 expression in allo-HSCT recipients results in
increased activation/maturation of DC leading to increased
alloactivation of donor T cells and worse GVHD.
Based on these observations in mice we analyzed a cohort of
122 allo-HSCT patients, who had received an allograft from a
HLA-identical sibling and found that the presence of ATG16L1
SNPs either in donor or recipient resulted in increased
mortality, although only donor ATG16L1 SNP reached statis-
tical signiﬁcance in this small cohort (P ¼ 0.026).
Taken together, our results in mouse and man suggest that
ATG16L1 and autophagy are involved in the pathophysiology
of GVHD and raise the possibility that strategies to induce
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